This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bobik, A. Search for Related Content PubMed PubMed Citation Articles by Bobik, A. Related Collections Cell signalling/signal transduction Lipid and lipoprotein metabolism

(Circulation. 2008;118:702-704.)
© 2008 American Heart Association, Inc.

Editorial

Apolipoprotein CIII and Atherosclerosis

Beyond Effects on Lipid Metabolism

Alex Bobik, PhD

From the Cell Biology Laboratory, Baker Heart Research Institute, Melbourne, Australia.

Correspondence to Alex Bobik, Cell Biology Laboratory, Baker Heart Research Institute, PO Box 6492 St Kilda Rd, Melbourne, Victoria 8008, Australia. E-mail alex.bobik@baker.edu.au

Key Words: Editorials • endothelium • lipoproteins • nitric oxide synthase

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The prevailing concept of mechanisms responsible for the development of atherosclerotic lesions largely focuses on the accumulation and retention of low-density lipoproteins in the arterial intima and their subsequent oxidative modification. This oxidation leads to activation of the endothelium, and particularly, expression of adhesion molecules that mediate leukocyte adherence and chemokines which initiate the inflammation reaction that is widely accepted as being responsible for the development and progression of atherosclerotic lesions.^1,2 There is also a strong body of evidence to indicate that elevated triacylglycerides (triglycerides) are an independent risk factor for atherosclerosis.^3–5

Article p 731

One mechanism that can contribute to elevated triglycerides involves apolipoprotein CIII (apoCIII). apoCIII is a small protein that resides on the surface of very-low-density lipoproteins (VLDLs), low-density lipoproteins, chylomicrons, and high-density lipoproteins (Figure). It exists as multiple species, as either a nonglycosylated isoform (apoCIII_o) or a glycosylated isoform (apoCIII₁ or apoCIII₂); all three isoforms have similar plasma half-lives and probably have very similar physiological functions. Increased apoCIII production is a characteristic feature of patients with hypertriglyceridemia,⁶ and plasma apoCIII levels have been positively correlated with plasma triacylglycerol concentrations and also have been associated with severity of hypertriglyceridemia.⁷ Elevated plasma apoCIII concentration and, specifically, accumulation of apoCIII in triacylglycerol-rich lipoproteins is casually related to hypertriglyceridemia in patients with metabolic syndrome and has also been associated with insulin resistance.⁸ apoCIII is a major regulator of lipolysis, as it noncompetitively inhibits endothelial-bound lipoprotein lipase, the enzyme that hydrolyzes triacylglycerols in triacylglycerol-rich lipoproteins, which generates . . . [Full Text of this Article]